Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered
- PMID: 26586938
- PMCID: PMC4636096
- DOI: 10.2147/DDDT.S93371
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered
Comment in
-
Authors’ reply.Drug Des Devel Ther. 2015;9:5875. Drug Des Devel Ther. 2015. PMID: 26918251 No abstract available.
Comment on
-
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.Drug Des Devel Ther. 2015 Jul 8;9:3435-44. doi: 10.2147/DDDT.S80928. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26185417 Free PMC article. Clinical Trial.
References
-
- Palmieri V, Dahlöf B, DeQuattro V, et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol. 1999;34(5):1625–1632. - PubMed
-
- Riegelman RK, Hirsch RP. Studying a study and testing a test. 3rd ed. Boston: Little, Brown and Company; 1996. Randomized clinical trials; pp. 69–91.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources